The CIRCADIAN Study: Evaluation of Modulating Effect of Galantamine on Circadian Rhythm in Patients With Mild to Moderate Alzheimer's Disease

Stopped The recruitment rate was very low (one screening failure and one early withdrawal patient)

Conditions

• Alzheimer Disease

Interventions

• DRUG: Galantamine

Sponsor

Janssen-Cilag, S.A.